Randomized Trial on the Effects of Dietary Potassium on Blood Pressure and Serum Potassium Levels in Adults with Chronic Kidney Disease.
Sharon TurbanStephen P JuraschekEdgar R MillerCheryl A M AndersonKaren WhiteJeanne CharlestonLawrence J AppelPublished in: Nutrients (2021)
In the general population, an increased potassium (K) intake lowers blood pressure (BP). The effects of K have not been well-studied in individuals with chronic kidney disease (CKD). This randomized feeding trial with a 2-period crossover design compared the effects of diets containing 100 and 40 mmol K/day on BP in 29 adults with stage 3 CKD and treated or untreated systolic BP (SBP) 120-159 mmHg and diastolic BP (DBP) <100 mmHg. The primary outcome was 24 h ambulatory systolic BP. The higher-versus lower-K diet had no significant effect on 24 h SBP (-2.12 mm Hg; p = 0.16) and DBP (-0.70 mm Hg; p = 0.44). Corresponding differences in clinic BP were -4.21 mm Hg for SBP (p = 0.054) and -0.08 mm Hg for DBP (p = 0.94). On the higher-K diet, mean serum K increased by 0.21 mmol/L (p = 0.003) compared to the lower-K diet; two participants had confirmed hyperkalemia (serum K ≥ 5.5 mmol/L). In conclusion, a higher dietary intake of K did not lower 24 h SBP, while clinic SBP reduction was of borderline statistical significance. Additional trials are warranted to understand the health effects of increased K intake in individuals with CKD.
Keyphrases
- blood pressure
- chronic kidney disease
- end stage renal disease
- weight loss
- hypertensive patients
- heart rate
- physical activity
- left ventricular
- fluorescent probe
- heart failure
- open label
- healthcare
- primary care
- double blind
- public health
- phase iii
- placebo controlled
- mental health
- phase ii
- study protocol
- type diabetes
- randomized controlled trial
- weight gain
- body mass index
- glycemic control